Antiarrhythmic drug usage and prostate cancer: a population-based cohort study

Area of Science:

• Cardiovascular Pharmacology
• Oncology
• Epidemiology

Background:

• Inconsistent findings exist regarding antiarrhythmic drug use and prostate cancer (PCa) risk.
• Limited research has explored the specific association between sodium or potassium channel blockers and PCa risk.

Purpose of the Study:

• To investigate the relationship between the use of various antiarrhythmic drugs and the risk of developing prostate cancer.
• To analyze the association between sodium channel blockers, potassium channel blockers, beta-blockers, calcium channel blockers, and digoxin with subsequent PCa risk.

Main Methods:

• A population-based cohort study utilizing the Longitudinal Health Insurance Database 2005 from Taiwan.
• Identification of cohorts for sodium channel blocker, potassium channel blocker, beta-blocker, calcium channel blocker, and digoxin users, each matched with non-users.
• A 5-year follow-up period using Cox proportional hazard regressions, adjusting for sociodemographic factors and comorbidities.

Main Results:

• Hazard ratios (HR) for PCa were: sodium channel blockers 1.12 (95% CI: 0.84-1.50), potassium channel blockers 0.89 (95% CI: 0.59-1.34), beta-blockers 1.08 (95% CI: 0.96-1.22), calcium channel blockers 1.14 (95% CI: 0.95-1.36), and digoxin 0.89 (95% CI: 0.67-1.18).
• No statistically significant associations were observed between the use of any antiarrhythmic drug class and the subsequent risk of prostate cancer.

Conclusions:

• The study concludes that there is no statistically significant association between the usage of different types of antiarrhythmic drugs and the subsequent risk of prostate cancer.
• Findings suggest that common antiarrhythmic medications do not appear to increase prostate cancer risk based on this population-based cohort analysis.